Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
47
BMRN Quote, Financials, Valuation and Earnings
Last price:
$56.85
Seasonality move
:
-1.65%
Day range:
$56.16 - $57.15
52-week range:
$50.76 - $73.51
Dividend yield:
0%
P/E ratio:
21.30x
P/S ratio:
3.60x
P/B ratio:
1.80x
Volume:
1.3M
Avg. volume:
2.7M
1-year change:
-8.01%
Market cap:
$10.9B
Revenue:
$2.8B
EPS (TTM):
$2.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$834.6M | $0.71 | 11.96% | 37.26% | $90.74 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 11.62% | 332.15% | $245.04 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.64 | -2.61% | 112.19% | $192.31 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
GILD
Gilead Sciences, Inc.
|
$7.7B | $1.86 | 4.32% | 94.73% | $136.55 |
|
MRK
Merck & Co., Inc.
|
$16.2B | $2.00 | 2.47% | -85.55% | $117.48 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$56.85 | $90.74 | $10.9B | 21.30x | $0.00 | 0% | 3.60x |
|
ABBV
AbbVie, Inc.
|
$223.93 | $245.04 | $395.8B | 168.97x | $1.73 | 2.97% | 6.65x |
|
BIIB
Biogen, Inc.
|
$174.12 | $192.31 | $25.5B | 15.88x | $0.00 | 0% | 2.63x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
GILD
Gilead Sciences, Inc.
|
$140.97 | $136.55 | $174.9B | 21.83x | $0.79 | 2.24% | 6.10x |
|
MRK
Merck & Co., Inc.
|
$107.92 | $117.48 | $267.9B | 14.28x | $0.85 | 3.04% | 4.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.914 | 5.87% | 2.84x |
|
ABBV
AbbVie, Inc.
|
104% | -0.205 | 16.8% | 0.47x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.665 | 32.07% | 1.77x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.024 | 18.1% | 1.16x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.108 | 20.79% | 1.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
ABBV
AbbVie, Inc.
|
$10.4B | $4.6B | 3.31% | 144.3% | 29.03% | $6.6B |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
BioMarin Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns BMRN or ABBV?
AbbVie, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 1.13%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B ABBVAbbVie, Inc.66.12% $0.10 $66.1B -
What do Analysts Say About BMRN or ABBV?
BioMarin Pharmaceutical, Inc. has a consensus price target of $90.74, signalling upside risk potential of 59.61%. On the other hand AbbVie, Inc. has an analysts' consensus of $245.04 which suggests that it could grow by 9.43%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than AbbVie, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.14 6 0 ABBVAbbVie, Inc.13 9 0 -
Is BMRN or ABBV More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.267, which suggesting that the stock is 73.343% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.359, suggesting its less volatile than the S&P 500 by 64.064%.
-
Which is a Better Dividend Stock BMRN or ABBV?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.97% to investors and pays a quarterly dividend of $1.73 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 263.15% of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or ABBV?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than AbbVie, Inc. quarterly revenues of $15.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than AbbVie, Inc.'s net income of $178M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 21.30x while AbbVie, Inc.'s PE ratio is 168.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.60x versus 6.65x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M ABBVAbbVie, Inc.6.65x 168.97x $15.8B $178M
-
Which has Higher Returns BMRN or BIIB?
Biogen, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 19%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About BMRN or BIIB?
BioMarin Pharmaceutical, Inc. has a consensus price target of $90.74, signalling upside risk potential of 59.61%. On the other hand Biogen, Inc. has an analysts' consensus of $192.31 which suggests that it could grow by 10.45%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Biogen, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.14 6 0 BIIBBiogen, Inc.14 18 1 -
Is BMRN or BIIB More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.267, which suggesting that the stock is 73.343% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.
-
Which is a Better Dividend Stock BMRN or BIIB?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or BIIB?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Biogen, Inc.'s net income of $466.5M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 21.30x while Biogen, Inc.'s PE ratio is 15.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.60x versus 2.63x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M BIIBBiogen, Inc.2.63x 15.88x $2.5B $466.5M
-
Which has Higher Returns BMRN or FOLD?
Amicus Therapeutics, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 10.24%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About BMRN or FOLD?
BioMarin Pharmaceutical, Inc. has a consensus price target of $90.74, signalling upside risk potential of 59.61%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.14 6 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is BMRN or FOLD More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.267, which suggesting that the stock is 73.343% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock BMRN or FOLD?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or FOLD?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 21.30x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.60x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns BMRN or GILD?
Gilead Sciences, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 39.21%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a consensus price target of $90.74, signalling upside risk potential of 59.61%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $136.55 which suggests that it could fall by -3.13%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.14 6 0 GILDGilead Sciences, Inc.17 7 0 -
Is BMRN or GILD More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.267, which suggesting that the stock is 73.343% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.
-
Which is a Better Dividend Stock BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.24% to investors and pays a quarterly dividend of $0.79 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or GILD?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 21.30x while Gilead Sciences, Inc.'s PE ratio is 21.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.60x versus 6.10x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M GILDGilead Sciences, Inc.6.10x 21.83x $7.8B $3.1B
-
Which has Higher Returns BMRN or MRK?
Merck & Co., Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 33.68%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About BMRN or MRK?
BioMarin Pharmaceutical, Inc. has a consensus price target of $90.74, signalling upside risk potential of 59.61%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.48 which suggests that it could grow by 8.86%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Merck & Co., Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.14 6 0 MRKMerck & Co., Inc.15 12 0 -
Is BMRN or MRK More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.267, which suggesting that the stock is 73.343% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.
-
Which is a Better Dividend Stock BMRN or MRK?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.04% to investors and pays a quarterly dividend of $0.85 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMRN or MRK?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 21.30x while Merck & Co., Inc.'s PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.60x versus 4.26x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.60x 21.30x $786.8M -$30.7M MRKMerck & Co., Inc.4.26x 14.28x $17.2B $5.8B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Alerts
Sell
11
CVLT alert for Jan 28
Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.
Sell
44
SANM alert for Jan 28
Sanmina Corp. [SANM] is down 21.58% over the past day.
Sell
16
HUM alert for Jan 28
Humana, Inc. [HUM] is down 21.11% over the past day.
